Niosomal l-carnitine and quercetin improve sperm quality and testicular function in atrazine-induced reproductive toxicity in rats
Niosome-encapsulated l-carnitine and quercetin partially reversed atrazine-induced sperm damage in rats — in groups of 5 animals each
Journal: Scientific Reports | Published: 2026-06-22 | Type: Animal study | PMID:42332019Authors: Azmi Omniya E et al. — nine authors across veterinary and pharmacy faculties at Minia University and Beni-Suef University, Egypt
Funding/COI: Funding not disclosed. Authors declare no competing interests. Ethics approval from Minia University animal care committee (IRB-FVM-MU-2024-108).
Summary
Atrazine, a widely used herbicide and suspected endocrine disruptor, was administered to adult male rats for 56 days to produce a model of reproductive toxicity. The researchers then tested whether l-carnitine (LC) or quercetin (QT), delivered either conventionally or encapsulated in niosomes (lipid-based nanoparticles), could reverse the damage. Both compounds showed partial rescue effects; the niosomal formulations outperformed the plain versions. The entire experiment ran on five rats per group.
Claims
ATZ reduced sperm concentration 3.06-fold, sperm motility 2.97-fold, and sperm viability 2.97-fold versus controls
ATZ decreased serum testosterone, FSH, and LH; elevated malondialdehyde (MDA); suppressed superoxide dismutase, catalase, and glutathione peroxidase activity
ATZ downregulated testicular mRNA expression of steroidogenic genes HSD3B, StAR, and CYP11A1
Histopathology showed degenerative changes in testes, epididymis, seminal vesicles, and prostate
Co-administration of LC or QT (conventional or niosomal) attenuated all of the above; niosomal forms (LCLN, QTLN) produced statistically greater restoration than conventional forms
Seminal vesicle weight loss caused by ATZ was not significantly recovered by any treatment (P > 0.05)
Study Quality
This is a controlled rodent experiment with six groups (control, ATZ alone, ATZ + LC, ATZ + LCLN, ATZ + QT, ATZ + QTLN), oral dosing for 56 days, and a reasonable multi-endpoint readout: sperm parameters, hormones, oxidative stress markers, gene expression, and histopathology. The niosomal formulations were characterized by particle size, PDI, zeta potential, and transmission electron microscopy, which is standard for this type of pharmaceutical work.
The fundamental problem is scale: 30 rats across six groups means five animals per group. That is below the threshold where statistical conclusions about biological effects are reliable. The paper reports p-values throughout, but with n=5, those p-values are extremely sensitive to single-animal outliers. No power calculation is reported. The study also has no groups testing LC or QT alone (without ATZ), which would be needed to determine whether these compounds have baseline reproductive effects independent of toxicity reversal.
Red Flags
Five rats per group. Any individual rat that performs differently swings the group mean dramatically. Results from groups this small should not be generalized.
Artificial toxicity model. The study measures rescue from a chemically induced insult, not treatment of naturally occurring infertility. Translation to clinical infertility populations is not established.
No funding disclosed. Unclear who paid for this work, including niosome synthesis and analytical instrumentation.
No LC-only or QT-only control groups. Impossible to distinguish treatment effect from toxicity rescue versus baseline biological activity of the compounds.
ATZ dose realism not discussed. The paper does not contextualize whether the administered atrazine dose represents environmentally plausible human exposure levels.
No sperm DNA integrity assays. Authors acknowledge in the limitations that SCD or Comet assays were not performed — a notable gap given atrazine's proposed genotoxic mechanisms.
No human applicability pathway. Authors explicitly state the lack of evaluation for human applicability in the limitations section.
All authors from veterinary faculties. The pharmaceutical niosome expertise appears to come from one pharmacy co-author; the primary team is veterinary medicine, which limits pharmacokinetic depth in the analysis.
Strengths
Multi-endpoint design (hormones + sperm + gene expression + histopathology) provides convergent evidence within the model
Niosomal formulations were characterized with standard methods (DLS, TEM, zeta potential) rather than assumed to work
Honest limitations section — the authors themselves flag the missing mechanistic work and human translation gap
Gene expression analysis of steroidogenic pathway (StAR, HSD3B, CYP11A1) adds mechanistic plausibility to the hormone findings
Verdict
This paper is methodologically coherent for what it is — a small-animal proof-of-concept for niosomal antioxidant delivery in a herbicide toxicity model — but it should not be read as evidence that l-carnitine or quercetin nanoparticles treat human infertility. Five rats per group is too few to draw reliable conclusions, the toxicity model does not map cleanly to clinical male infertility, and no human data exist. The niosome formulation work is technically reasonable and could justify a larger follow-up study. File this under "preliminary rodent pharmacology" and wait for replication in a properly powered animal study before the human conversation begins.